Overview

CJC-1295 (No DAC), also referred to as Modified GRF (1–29), is a synthetic peptide derived from the N-terminal 29–amino acid sequence of endogenous growth hormone–releasing hormone (GHRH). This modified analogue incorporates targeted amino-acid substitutions designed to improve resistance to enzymatic degradation while preserving receptor-binding activity in experimental systems.

Unlike DAC-conjugated variants, the no-DAC format retains a short-acting signaling profile, making it suitable for laboratory investigations focused on early-phase receptor activation, signal initiation, and transient endocrine pathway dynamics. All descriptions of CJC-1295 (No DAC) are limited to controlled non-clinical research settings.

This material is supplied strictly for research use only and is not intended for human or veterinary application.

Biochemical Characteristics

Additional structural modifications, including D-amino acid substitution and C-terminal amidation, are commonly described in the literature to support peptide integrity during in-vitro and in-vivo experimental workflows.

Research Applications

In scientific literature, CJC-1295 (No DAC) is employed as a research tool for examining growth hormone–releasing hormone receptor engagement and downstream intracellular signaling cascades. Its non-DAC configuration allows researchers to study rapid signaling events without prolonged receptor occupancy.

Reported research uses include investigation of:

• GHRHR binding affinity and activation kinetics

• Adenylate cyclase stimulation and cyclic AMP signaling

• Short-duration somatotropic pathway activation

• Comparative studies of GHRH analog structure–activity relationships

• Pituitary receptor regulation in cellular and animal models

All applications are confined to experimental laboratory environments.

Pathway / Mechanistic Context

Mechanistic studies describe CJC-1295 (No DAC) as an agonist of the GHRH receptor, a class B G-protein–coupled receptor primarily linked to Gs signaling pathways. Receptor activation initiates adenylate cyclase activity, resulting in elevated intracellular cAMP levels and engagement of protein kinase A–dependent signaling networks.

This signaling framework is used in preclinical research to evaluate receptor specificity, temporal signaling behavior, second-messenger amplification, and feedback regulation within endocrine and neuroendocrine model systems. No functional or physiological outcomes beyond laboratory observation are implied.

Preclinical Research Summary

Preclinical investigations utilizing Modified GRF (1–29) have focused on receptor activation profiles, intracellular signaling kinetics, and comparative potency relative to other GHRH analogues. In cell-based systems, studies often assess cAMP production and downstream transcriptional responses following receptor engagement.

Animal model studies referenced in the literature explore peptide distribution and endocrine signaling behavior under defined experimental protocols. All reported findings are derived exclusively from non-clinical research models and do not establish clinical relevance.

Form, Handling & Analytical Testing

CJC-1295 (No DAC) is supplied as a research-grade synthetic peptide material. Identity and purity are evaluated using analytical techniques standard to peptide research, including chromatographic separation and mass spectrometric characterization.

Research Use Disclaimer

This product is intended for laboratory research use only.
Not for human consumption, clinical use, diagnostic application, or veterinary use.
No therapeutic claims or clinical outcomes are expressed or implied.

Important Legal & Educational Notice

This document is provided solely for general educational and informational purposes. It does NOT provide medical advice, legal advice, dosing guidance, treatment instructions, or recommendations of any kind. Nothing in this document recommends, suggests, instructs, or endorses the use of any peptide, compound, injection technique, dosage, timing, frequency, or anatomical site. All information must be independently verified with a licensed medical professional. This document is intended to comply with applicable laws and regulations of the State of California.